Business
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application Financing led by Coastlands Capital with participation from new and existing biotechnology investors Initial proceeds extend cash runway into the first half of 2027 NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8Bio” or the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical com
About this update from In8bio, Inc.
[{"type":"image","alt":"IN8bio, Inc","displaySize":"","headline":null,"caption":"IN8bio, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":149,"url":"https://media.zenfs.com/en/globenewswire.com/2eaff8c6754066d4f7498c1179b53d18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LM3P9KMIYObIbb2x2kkziw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2eaff8c6754066d4f7498c1179b53d18","width":300,"height":149}},"lazy":false},{"type":"text","content":"$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application","length":195,"tagName":"p"},{"type":"text","content":"Financing led by Coastlands Capital with participation from new and existing biotechnology investors ","length":100,"tagName":"p"},{"type":"text","content":"Initial proceeds extend cash runway into the first half of 2027","length":63,"tagName":"p"},{"type":"text","content":"NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8Bio” or the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative γδ T cell therapies for cancer and autoimmune diseases, today announced that it has entered into a definitive securities purchase agreement (“SPA”) with certain institutional and accredited investors for up to approximately $40.2 million in gross proceeds through a private placement, priced at-the-market under Nasdaq rules. The net proceeds from the initial tranche of the financing are expected to fund the Company’s current operating plans into the first half of 2027.","length":638,"tagName":"p"},{"type":"text","content":"The private placement includes new and existing investors including Coastlands Capital, Stonepine Capital Management and 683 Capital Partners, LP along with directors and officers of the Company.","length":195,"tagName":"p"},{"type":"text","content":"H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement.","length":95,"tagName":"p"},{"type":"text","content":"Under the terms of the SPA, the private placement includes an initial closing of approximately $20.1 million in gross proceeds. At the initial closing, the Company will sell 5,127,029 shares of common stock at a purchase price of $1.38...